These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 25189101

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Predictors for long-term seizure outcome in juvenile myoclonic epilepsy: 25-63 years of follow-up.
    Geithner J, Schneider F, Wang Z, Berneiser J, Herzer R, Kessler C, Runge U.
    Epilepsia; 2012 Aug; 53(8):1379-86. PubMed ID: 22686598
    [Abstract] [Full Text] [Related]

  • 4. Seizure outcome in 175 patients with juvenile myoclonic epilepsy--a long-term observational study.
    Höfler J, Unterberger I, Dobesberger J, Kuchukhidze G, Walser G, Trinka E.
    Epilepsy Res; 2014 Dec; 108(10):1817-24. PubMed ID: 25443450
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Juvenile myoclonic epilepsy refractory to treatment in a tertiary referral center.
    Cação G, Parra J, Mannan S, Sisodiya SM, Sander JW.
    Epilepsy Behav; 2018 May; 82():81-86. PubMed ID: 29602081
    [Abstract] [Full Text] [Related]

  • 8. High-dose versus low-dose valproate for the treatment of juvenile myoclonic epilepsy: Going from low to high.
    Hernández-Vanegas LE, Jara-Prado A, Ochoa A, Rodríguez Y Rodríguez N, Durón RM, Crail-Meléndez D, Alonso ME, Delgado-Escueta AV, Martínez-Juárez IE.
    Epilepsy Behav; 2016 Aug; 61():34-40. PubMed ID: 27300146
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prognosis of juvenile myoclonic epilepsy 45 years after onset: seizure outcome and predictors.
    Senf P, Schmitz B, Holtkamp M, Janz D.
    Neurology; 2013 Dec 10; 81(24):2128-33. PubMed ID: 24212391
    [Abstract] [Full Text] [Related]

  • 12. Levetiracetam and Valproate Retention Rate in Juvenile Myoclonic Epilepsy.
    Sala-Padró J, Toledo M, Santamarina E, González-Cuevas M, Raspall-Chaure M, Sueiras-Gil M, Quintana M, Salas-Puig X.
    Clin Neuropharmacol; 2016 Dec 10; 39(6):299-301. PubMed ID: 27438183
    [Abstract] [Full Text] [Related]

  • 13. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy.
    Prasad A, Kuzniecky RI, Knowlton RC, Welty TE, Martin RC, Mendez M, Faught RE.
    Arch Neurol; 2003 Aug 10; 60(8):1100-5. PubMed ID: 12925366
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phenotyping juvenile myoclonic epilepsy. Praxis induction as a biomarker of unfavorable prognosis.
    Uchida CG, de Carvalho KC, Guaranha MS, Guilhoto LM, de Araújo Filho GM, Wolf P, Yacubian EM.
    Seizure; 2015 Nov 10; 32():62-8. PubMed ID: 26552565
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Characteristics of valproic acid resistant juvenile myoclonic epilepsy.
    Fernando-Dongas MC, Radtke RA, VanLandingham KE, Husain AM.
    Seizure; 2000 Sep 10; 9(6):385-8. PubMed ID: 10985993
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate.
    Chowdhury A, Brodie MJ.
    Epilepsy Res; 2016 Jan 10; 119():62-6. PubMed ID: 26675554
    [Abstract] [Full Text] [Related]

  • 20. Outcomes of low-dose valproic acid treatment in patients with juvenile myoclonic epilepsy.
    Gürer R, Aydın Ş, Özkara Ç.
    Seizure; 2019 Aug 10; 70():43-48. PubMed ID: 31252363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.